Oct 27, 2024 · TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help …

TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.

Aug 28, 2024 · The manufacturer is selling single-dose vials of the drug via its online pharmacy at around $400 to $500 for a 4-week supply.

Oct 17, 2024 · TCT 2024, the annual scientific showcase of interventional cardiovascular medicine, is returning once again to Washington, DC. The 4-day meeting starts Sunday, …

Dec 29, 2024 · It was a big news year for structural heart disease. For tricuspid regurgitation, two devices were approved in quick succession by the US Food and Drug Administration, then …

Dec 31, 2024 · This month, as we wrap up 2024, our top 10 list covered quite broad ground. There were reimbursement woes and social media shifts, plus good news for the dual …

Nov 16, 2024 · CHICAGO, IL—Tirzepatide (Eli Lilly) significantly cut the risk of cardiovascular mortality and worsening heart failure events by nearly 40% over a median follow-up of roughly …

Dec 30, 2024 · For general cardiology and prevention, the year 2024 was all about novel treatments for new targets—be those lipoprotein(a), glucagon-like peptide-1 (GLP-1), or …

Dec 4, 2024 · In a head-to-head tussle between two obesity drugs, tirzepatide came out on top of semaglutide for weight loss, according to topline results from the SURMOUNT-5 trial released …

Oct 28, 2024 · Disclosures. EARLY TAVR was sponsored by Edwards Lifesciences. Généreux reports consulting for and/or receiving speaking fees from Abbott Vascular, Abiomed, Boston …